Search

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes. Current members of EHA's Executive Board

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

Jun 13 2014 Posted in Press releases

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Board elections

All members* who have paid their annual fees, have the privilege to influence the composition of the EHA Board. We need your involvement in the selection of EHA’s governmental body.

Mentoring peer-peer networks – a recipe for success

Oct 28 2019

Isabel Peset1 & Alba Maiques-Diaz2

1 Senior Scientist, Microscopy, Medicines Discovery Catapult, Manchester, UK;
2 Postdoctoral scientist, Biomedical Epigenomics group, IDIBAPS, Barcelona, Spain; YoungEHA committee member.

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Jun 14 2013

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.